BioSpace News Archive

Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022

Full Year Revenue Increase of 15% Management to Host Conference Call Today at 5:00 pm ET

SOPHiA GENETICS SA (“SOPHiA GENETICS”), pioneer in Data-Driven Medicine, and Hitachi, Ltd. (TSE: 6501, “Hitachi”) today announced they have entered into a long-term collaboration agreement to bring clinical, genomic and real-world insights to healthcare providers

PPJ Enterprise (Trading Symbol: OTC PINK:PPJE), a leader in Healthcare Reimbursement Cycle Expert for Complex Medical/Surgical Services and proprietary Automated Healthcare Practice Management Software, online Health Information Digital Systems and Medical Practice Information Management, is pleased to announce that the company signed new medical billing client.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced the identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2020 and fiscal year 2020.

Immuneering Corporation today announced Carolina Garcia Rizo, Ph.D., MBA, has joined the company as chief business officer. Dr. Rizo brings to Immuneering extensive experience in the biotech and pharmaceutical industries, including senior-level leadership roles in global business development and strategy, machine learning (ML) based product development and commercial operations.

Therma’s clinical research organization prepared and filed the necessary documentation for the IRB and Health Canada submissions.

Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab).

Today, the Biden administration announced a new partnership with dialysis providers to provide COVID-19 vaccinations to people receiving dialysis and health care personnel in outpatient dialysis centers.